Theravance Biopharma Business Summary

Theravance Biopharma, Inc. (TBPH) is a diversified biopharmaceutical company that generates revenue primarily through the commercialization of its FDA-approved respiratory therapy, YUPELRI (revefenacin), and strategic licensing and collaboration agreements. The company’s business model is centered on the discovery and development of organ-selective small-molecule medicines designed to maximize therapeutic efficacy while minimizing systemic side effects. Its primary business segments focus on inflammation and immunology, with a specialized emphasis on lung-selective treatments for chronic obstructive pulmonary disease (COPD) and late-stage candidates like ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH). Within the competitive landscape, Theravance Biopharma contends with major players such as Biohaven, Kiniksa Pharmaceuticals, and Viking Therapeutics. The company distinguishes itself as a niche leader in organ-selective pharmacology, positioning its portfolio to address high-unmet-need respiratory and rare disease markets where systemic toxicity often limits standard-of-care treatments. Theravance Biopharma was established as a spin-off from Innoviva, Inc. (formerly Theravance, Inc.) in 2014, led by Chief Executive Officer Rick E. Winningham, who previously served as CEO of Innoviva and held senior executive roles at Bristol-Myers Squibb. The current leadership team includes Chief Financial Officer Aziz Sawaf, who joined in 2014 after a tenure at Gilead Sciences, and Rhonda Farnum, the Chief Business Officer and SVP of Commercial and Medical Affairs, who brings extensive oncology and commercial experience from Amgen. The company’s scientific direction is spearheaded by Dr. Sharathchandra Hegde, Senior Vice President of Research, an original member of the Theravance leadership with over two decades of drug discovery expertise. The Board of Directors features notable industry veterans including Chair Susannah Gray, former CFO of Royalty Pharma, and Dr. Deepika Pakianathan of Delphi Ventures. Institutional backing remains robust, with significant positions held by major investors such as Oasis Management, State Street Corporation, and The Vanguard Group.